Background and purpose Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with limited treatment options. RNS60 is an immunomodulatory and neuroprotective investigational product that has shown efficacy in animal models of ALS and other neurodegenerative diseases. Its administration has been safe and well tolerated in ALS subjects in previous early phase trials. Methods This was a phase II, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial. Participants diagnosed with definite, probable or probable laboratory-supported ALS were assigned to receive RNS60 or placebo administered for 24 weeks intravenously (375 ml) once a week and via nebulization (4 ml/day) on non-infusion days, followed by an additional 24 weeks off-treatment. The primary objective was to measure the effects of RNS60 treatment on selected biomarkers of inflammation and neurodegeneration in peripheral blood. Secondary objectives were to measure the effect of RNS60 on functional impairment (ALS Functional Rating Scale-Revised), a measure of self-sufficiency, respiratory function (forced vital capacity, FVC), quality of life (ALS Assessment Questionnaire-40, ALSAQ-40) and survival. Tolerability and safety were assessed. Results Seventy-four participants were assigned to RNS60 and 73 to placebo. Assessed biomarkers did not differ between arms. The mean rate of decline in FVC and the eating and drinking domain of ALSAQ-40 was slower in the RNS60 arm (FVC, difference 0.41 per week, standard error 0.16, p = 0.0101; ALSAQ-40, difference -0.19 per week, standard error 0.10, p = 0.0319). Adverse events were similar in the two arms. In a post hoc analysis, neurofilament light chain increased over time in bulbar onset placebo participants whilst remaining stable in those treated with RNS60. Conclusions The positive effects of RNS60 on selected measures of respiratory and bulbar function warrant further investigation.
Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, double-blind, placebo-controlled trial / Beghi, Ettore; Pupillo, Elisabetta; Bianchi, Elisa; Bonetto, Valentina; Luotti, Silvia; Pasetto, Laura; Bendotti, Caterina; Tortarolo, Massimo; Sironi, Francesca; Camporeale, Laura; Sherman, Alexander V; Paganoni, Sabrina; Scognamiglio, Ada; De Marchi, Fabiola; Bongioanni, Paolo; Del Carratore, Renata; Caponnetto, Claudia; Diamanti, Luca; Martinelli, Daniele; Calvo, Andrea; Filosto, Massimiliano; Padovani, Alessandro; Piccinelli, Stefano Cotti; Ricci, Claudia; Dalla Giacoma, Stefania; De Angelis, Nicoletta; Inghilleri, Maurizio; Spataro, Rossella; La Bella, Vincenzo; Logroscino, Giancarlo; Lunetta, Christian; Tarlarini, Claudia; Mandrioli, Jessica; Martinelli, Ilaria; Simonini, Cecilia; Zucchi, Elisabetta; Monsurrò, Maria Rosaria; Ricciardi, Dario; Trojsi, Francesca; Riva, Nilo; Filippi, Massimo; Simone, Isabella Laura; Sorarù, Gianni; Spera, Cristina; Florio, Lucia; Messina, Sonia; Russo, Massimo; Siciliano, Gabriele; Conte, Amelia; Saddi, Maria Valeria; Carboni, Nicola; Mazzini, Letizia. - In: EUROPEAN JOURNAL OF NEUROLOGY. - ISSN 1351-5101. - 30:1(2023), pp. 69-86. [10.1111/ene.15573]
Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, double-blind, placebo-controlled trial
Mandrioli, Jessica;Martinelli, Ilaria;Zucchi, Elisabetta;
2023
Abstract
Background and purpose Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with limited treatment options. RNS60 is an immunomodulatory and neuroprotective investigational product that has shown efficacy in animal models of ALS and other neurodegenerative diseases. Its administration has been safe and well tolerated in ALS subjects in previous early phase trials. Methods This was a phase II, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial. Participants diagnosed with definite, probable or probable laboratory-supported ALS were assigned to receive RNS60 or placebo administered for 24 weeks intravenously (375 ml) once a week and via nebulization (4 ml/day) on non-infusion days, followed by an additional 24 weeks off-treatment. The primary objective was to measure the effects of RNS60 treatment on selected biomarkers of inflammation and neurodegeneration in peripheral blood. Secondary objectives were to measure the effect of RNS60 on functional impairment (ALS Functional Rating Scale-Revised), a measure of self-sufficiency, respiratory function (forced vital capacity, FVC), quality of life (ALS Assessment Questionnaire-40, ALSAQ-40) and survival. Tolerability and safety were assessed. Results Seventy-four participants were assigned to RNS60 and 73 to placebo. Assessed biomarkers did not differ between arms. The mean rate of decline in FVC and the eating and drinking domain of ALSAQ-40 was slower in the RNS60 arm (FVC, difference 0.41 per week, standard error 0.16, p = 0.0101; ALSAQ-40, difference -0.19 per week, standard error 0.10, p = 0.0319). Adverse events were similar in the two arms. In a post hoc analysis, neurofilament light chain increased over time in bulbar onset placebo participants whilst remaining stable in those treated with RNS60. Conclusions The positive effects of RNS60 on selected measures of respiratory and bulbar function warrant further investigation.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Euro J of Neurology - 2022 - Beghi - Effect of RNS60 in amyotrophic lateral sclerosis a phase II multicentre randomized .pdf
Open access
Tipologia:
Versione pubblicata dall'editore
Dimensione
1.55 MB
Formato
Adobe PDF
|
1.55 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
